Biologic Agents for Inflammatory Bowel Disease in the UK
The following biologics are approved for IBD in the UK, with specific dosing regimens, routes, and expected response timeframes based on current BSG guidelines and clinical evidence.
Anti-TNF Agents
Infliximab (Remicade)
- Dosing: 5 mg/kg IV at weeks 0,2,6, then every 8 weeks for maintenance
- Route: Intravenous infusion
- Time to response: Clinical response typically within 2-4 weeks; endoscopic remission assessed at 8-12 weeks
- Notes: First-line option for moderate-to-severe UC and CD, particularly with penetrating phenotype or multiple extraintestinal manifestations 1, 2. Consider combining with purine analogues in UC 1.
Adalimumab (Humira)
- Dosing: 160 mg SC at week 0,80 mg at week 2, then 40 mg every 2 weeks
- Route: Subcutaneous injection
- Time to response: Clinical response within 2-4 weeks; full assessment at 8-12 weeks
- Notes: Preferred first-line for CD with penetrating disease or EIMs 2. Effectiveness may decrease after prior anti-TNF exposure 3.
Golimumab (Simponi)
- Dosing: 200 mg SC at week 0,100 mg at week 2, then 100 mg every 4 weeks (or 50 mg for patients <80 kg)
- Route: Subcutaneous injection
- Time to response: Clinical response within 4-6 weeks
- Notes: Approved for moderate-to-severe UC 4.
Anti-Integrin Agents
Vedolizumab (Entyvio)
- Dosing: 300 mg IV at weeks 0,2,6, then every 8 weeks
- Route: Intravenous infusion
- Time to response: Clinical response may take 6-10 weeks; full effect often not seen until 14-16 weeks
- Notes: Superior first-line effectiveness in UC compared to anti-TNF agents over 5 years 5. Gut-selective with favorable safety profile 2. Effectiveness not significantly impacted by prior anti-TNF exposure 3, 5.
IL-12/23 Inhibitor
Ustekinumab (Stelara)
- Dosing:
- Induction: Weight-based IV (260 mg for ≤55 kg, 390 mg for 55-85 kg, 520 mg for >85 kg) at week 0
- Maintenance: 90 mg SC every 8-12 weeks starting at week 8
- Route: IV induction, then SC maintenance
- Time to response: Clinical response within 6-8 weeks; endoscopic assessment at 16-24 weeks
- Notes: Reasonable first-line option for CD with inflammatory phenotype 2. Effectiveness maintained regardless of prior anti-TNF exposure 3.
IL-23 Inhibitor
Risankizumab (Skyrizi)
- Dosing: 600 mg IV at weeks 0,4,8, then 360 mg SC every 8 weeks
- Route: IV induction, then SC maintenance
- Time to response: Clinical response within 4-8 weeks; endoscopic remission assessed at 12-16 weeks
- Notes: Effectiveness not impacted by prior anti-TNF therapy 3. Approved for moderate-to-severe CD.
S1P Receptor Modulator
Ozanimod (Zeposia)
- Dosing:
- Days 1-4: 0.23 mg daily
- Days 5-7: 0.46 mg daily
- Day 8 onwards: 0.92 mg daily
- Route: Oral
- Time to response: Clinical response within 8-10 weeks
- Notes: Approved for moderate-to-severe UC. Effectiveness maintained after prior anti-TNF exposure 3.
JAK Inhibitors
Tofacitinib (Xeljanz)
- Dosing:
- Induction: 10 mg oral twice daily for 8 weeks
- Maintenance: 5 mg twice daily (can increase to 10 mg twice daily if needed)
- Route: Oral
- Time to response: Rapid onset, clinical response within 2-4 weeks
- Notes: Approved for moderate-to-severe UC. Effectiveness not reduced by prior anti-TNF therapy 3. Requires monitoring for thromboembolic events.
Upadacitinib (Rinvoq)
- Dosing:
- Induction: 45 mg oral once daily for 8 weeks
- Maintenance: 15 mg or 30 mg once daily
- Route: Oral
- Time to response: Rapid onset, clinical response within 2-4 weeks
- Notes: Approved for moderate-to-severe UC. Effectiveness maintained regardless of prior anti-TNF exposure 3.
Treatment Sequencing Considerations
After first anti-TNF failure in UC, vedolizumab demonstrates superior effectiveness compared to switching to a second anti-TNF 5. In CD, non-anti-TNF biologics are superior to a second anti-TNF after first-line anti-TNF failure 5.
Key Sequencing Principles:
- UC first-line: Vedolizumab or infliximab preferred 2, 5
- CD with penetrating disease/EIMs: Infliximab or adalimumab first-line 2
- CD inflammatory phenotype: Anti-TNF, vedolizumab, or ustekinumab all reasonable 2
- After anti-TNF failure: Switch to non-anti-TNF biologic (vedolizumab, ustekinumab, risankizumab) or JAK inhibitor rather than second anti-TNF 5
- After vedolizumab failure: Anti-TNF effectiveness not significantly impacted 3, 5
Critical Timing Considerations
Live vaccinations (including varicella) must be administered at least 4 weeks before starting biologic therapy, and should be avoided during therapy and for minimum 3 months after stopping 1. Plan vaccination windows carefully before initiating immunosuppression.